Autoimmune polyendocrine syndrome epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
Akshun Kalia (talk | contribs) (→Gender) |
Akshun Kalia (talk | contribs) No edit summary |
||
| Line 6: | Line 6: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence | *The incidence of autoimmune polyendocrine syndrome (APS) type 2 is estimated to be 1-2 per 100,000 individuals worldwide. | ||
* | *The most common autoimmune polyendocrine syndrome seen in general population is APS type 2. | ||
*APS type 1 and type 3 are very rare and extremely rare conditions respectively. Therefore no precise data is available for their incidence. | |||
===Prevalence=== | ===Prevalence=== | ||
*The | *The prevalence of autoimmune polyendocrine syndrome (APS) type 2 is estimated to be 1-4 per 100,000 individuals worldwide. | ||
* | *APS type 1 and type 3 are very rare and extremely rare conditions respectively. Therefore no precise data is available for their prevalence. | ||
*The prevalence of | *APS type 1 is a very rare disorder and seen mostly in Iran, Sardinia and Finland. | ||
**The prevalence of APS type is estimated to be 11 cases per 100,000 in Iranian Jews. | |||
* | **The prevalence of APS type is estimated to be 7 cases per 100,000 in Sardinians. | ||
**The prevalence of APS type is estimated to be 4 cases per 100,000 in Finland. | |||
*The prevalence of | |||
===Age=== | ===Age=== | ||
*Autoimmune polyendocrine syndrome (APS) type 1 commonly affects children in the age group of 3-5 or in 13-15 years of age. | *Autoimmune polyendocrine syndrome (APS) type 1 commonly affects children in the age group of 3-5 or in 13-15 years of age. | ||
*Autoimmune polyendocrine syndrome (APS) type 2 commonly affects adults in the third and fourth decade of life. | *Autoimmune polyendocrine syndrome (APS) type 2 commonly affects adults in the third and fourth decade of life. | ||
*Autoimmune polyendocrine syndrome (APS) type 3 commonly affects 40-60 years old women but may occur in any age group. | |||
*Most cases of autoimmune polyendocrine syndrome (APS) type 1 and type 2 are symptomatic by early thirties. | *Most cases of autoimmune polyendocrine syndrome (APS) type 1 and type 2 are symptomatic by early thirties. | ||
===Race=== | ===Race=== | ||
* | *Autoimmune polyendocrine syndrome (APS) usually affects individuals of the caucasian race. | ||
===Gender=== | ===Gender=== | ||
*In autoimmune polyendocrine syndrome type 1 and type | *In autoimmune polyendocrine syndrome type 1, type 2 and type 3 females are more commonly affected than men. | ||
===Region=== | ===Region=== | ||
*The majority of autoimmune polyendocrine syndrome cases are reported in Finland and Iran | *The majority of autoimmune polyendocrine syndrome type 1 cases are reported in Finland, Sardinia and Iran. It can be attributed to consanguineous marriages and/or clustering of descendants of common family founders. Other less frequent regions include Norway, Germany, northern Italy and northern Britain. | ||
==References== | ==References== | ||
Revision as of 19:04, 2 October 2017
|
Autoimmune polyendocrine syndrome Microchapters |
|
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Autoimmune polyendocrine syndrome epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome epidemiology and demographics |
|
FDA on Autoimmune polyendocrine syndrome epidemiology and demographics |
|
CDC on Autoimmune polyendocrine syndrome epidemiology and demographics |
|
Autoimmune polyendocrine syndrome epidemiology and demographics in the news |
|
Blogs on Autoimmune polyendocrine syndrome epidemiology and demographics |
|
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Epidemiology and Demographics
Incidence
- The incidence of autoimmune polyendocrine syndrome (APS) type 2 is estimated to be 1-2 per 100,000 individuals worldwide.
- The most common autoimmune polyendocrine syndrome seen in general population is APS type 2.
- APS type 1 and type 3 are very rare and extremely rare conditions respectively. Therefore no precise data is available for their incidence.
Prevalence
- The prevalence of autoimmune polyendocrine syndrome (APS) type 2 is estimated to be 1-4 per 100,000 individuals worldwide.
- APS type 1 and type 3 are very rare and extremely rare conditions respectively. Therefore no precise data is available for their prevalence.
- APS type 1 is a very rare disorder and seen mostly in Iran, Sardinia and Finland.
- The prevalence of APS type is estimated to be 11 cases per 100,000 in Iranian Jews.
- The prevalence of APS type is estimated to be 7 cases per 100,000 in Sardinians.
- The prevalence of APS type is estimated to be 4 cases per 100,000 in Finland.
Age
- Autoimmune polyendocrine syndrome (APS) type 1 commonly affects children in the age group of 3-5 or in 13-15 years of age.
- Autoimmune polyendocrine syndrome (APS) type 2 commonly affects adults in the third and fourth decade of life.
- Autoimmune polyendocrine syndrome (APS) type 3 commonly affects 40-60 years old women but may occur in any age group.
- Most cases of autoimmune polyendocrine syndrome (APS) type 1 and type 2 are symptomatic by early thirties.
Race
- Autoimmune polyendocrine syndrome (APS) usually affects individuals of the caucasian race.
Gender
- In autoimmune polyendocrine syndrome type 1, type 2 and type 3 females are more commonly affected than men.
Region
- The majority of autoimmune polyendocrine syndrome type 1 cases are reported in Finland, Sardinia and Iran. It can be attributed to consanguineous marriages and/or clustering of descendants of common family founders. Other less frequent regions include Norway, Germany, northern Italy and northern Britain.